Assessment of HTLV-I proviral load, HIV viral load and CD4 T cell count in infected subjects; with an emphasis on viral replication in co-infection

Hossein Rahimi 1, Seyyed Abdolrahim Rezaee 2, Narges Valizade 3, Rosita Vakili 3, Houshang Rafatpanah 3*

1 Hematology Department, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Immunology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 Inflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

ABSTRACT

Objectives: HTLV-I and HIV virus quantification is an important marker for assessment of virus activities. Since there is a direct relationship between the number of virus and disease progression, HTLV-I and HIV co-infection might have an influence on the development of viral associated diseases, thus, viral replication of these viruses and co-infection were evaluated.

Materials and Methods: In this study, 40 subjects were selected; 14 HIV infected, 20 HTLV-I infected and 6 HTLV-I/HIV co-infected subjects. The amount of viruses was measured using qPCR TaqMan method and CD4 and CD8 lymphocytes were assessed by flow cytometry.

Results: The mean viral load of HIV infected subjects and HTLV-I infected individuals were 13462.6 ± 6031.07 copies/ml and 373.6 ± 433.3 copies/106 cells, respectively. The mean HIV viral load in co-infected group was 1599472 ± 820359 copies/ml which is higher than HIV infected group. The mean proviral load of HTLV-I in co-infected group was 222.3 ± 82.5 copies/ml which is lower than HTLV-I infected group (P < 0.05). Also, the mean white blood cell count was higher in co-infected group (5666.67 ± 1146.49 cells/µl). However, the differences between these subjects did not reach to a statistical significance within 95% confidence interval level (P > 0.1). No significant differences were observed regarding CD4 and CD8 positive lymphocytes between these groups.

Conclusion: HTLV-I/HIV co-infection might promote HIV replication and could reduce the HTLV-I proviral load, in infected cells. Considering the presence of both viruses in Khorasan provinces, it encourages researchers and health administrators to have a better understanding of co-infection outcome.

Introduction

Human immunodeficiency virus (HIV) is a lentivirus belonging to Retroviridae family. This virus mostly infects CD4+ T lymphocytes which have a crucial role in immune regulation and causes immunodeficiency syndrome (AIDS) by severe lymphocyte depletion. A global total of 40 million people were diagnosed with HIV infection in 2012 and almost 5 million people were reported as newly infected individuals (1-3). Based on the AIDS progress report in 2012, HIV prevalence in Iran has been significantly increased. Therefore, effective control and prevention of HIV and also appropriate monitoring of HIV infected individuals must be implemented as major health programs in Iran (4). Since plasma HIV-I RNA level is an independent predictor of HIV disease progression, its measurement is important to evaluate the efficacy of antiretroviral drug therapies and to monitor disease progression in HIV infected individuals (5-6).

Human T lymphotropic virus type I (HTLV-I) is a retrovirus belonging to Retroviridae family and associated with two main types of diseases; adult T-cell leukemia (ATL) and the inflammatory condition named HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) (7-8). This virus is endemic in several regions of the world, such as southwest of Japan, the Caribbean basin, Central Africa, South America, the Melanesian Islands and the Middle East (9-10). HTLV-I is endemic in at least 5 provinces of Iran including Khorasan Razavi, Northern Khorasan, Golestan, Alborz and Eastern Azarbayjan (11-13). The prevalence of HTLV-I...
infection in Iran is estimated to vary among 24 provinces (14).

HTLV-I proviral load is a major determinant of HTLV-I infection outcome and higher HTLV-I proviral load as well as the interaction between the virus and the host have crucial role in the development of HTLV-I associated diseases (15-16).

Both HTLV-I and HTLV-II are frequent co pathogens among individuals infected with HIV in different parts of the world. HTLV-I and HIV share similar routes of transmission and predominantly are CD4+ T cell tropic (8, 17-19). Several studies have demonstrated a protective effect on AIDS progression by HTLV-II (8, 17, 20). Furthermore, an increased frequency of other clinical complications has been reported in HIV-HTLV-I/II co-infection (21). Some laboratory evidences suggested that AIDS progression is promoted by HTLV-I/HTLV-I co-infection. However, the net impact of HTLV-I/HTLV-I co-infection on HIV disease is still controversial (8, 22). It seems that introduction of highly active antiretroviral therapy (HAART), has been led to longer survival for HIV-infected individuals and stops HIV replication, but does not have any protective impact on HTLV proviral load, CD4 cell count and HAM/TSP development (18-19, 23-25).

The obvious outcome of HTLV-I or HTLV-II and HIV co-infection is an increased CD4+ cells count without any immune benefit for patients (26-27). Furthermore, some studies have reported that the risk of developing HAM/TSP in HIV-HTLV-I co-infected patients is higher than in HTLV-I-infected individuals and it may be due to the higher HTLV proviral load in co-infected patients (18, 22, 28-29). Understanding the effect of HTLV-I virus on HIV viral replication and vice versa, will help for better monitoring and following up of HIV and HTLV-I-associated diseases in this endemic area.

Materials and Methods

Study design

A total of 112 HIV positive subjects were recruited from triangular clinic, Mashhad University of Medical Sciences, Mashhad, Iran from January 2001 to 2010. This clinic is the only one in Khorasan Razavi province providing a wide-range of counseling and treatment for HIV positive subjects. Only the patients who were asymptomatic at the time of admission to the clinic (WHO stage I) and those newly diagnosed asymptomatic HTLV-I cases were included in this study. Including criteria were as follow; newly diagnosed untreated subjects, non IV drug users, Khorasani residents and healthy carriers without any diseases symptoms at the time of sampling. Forty subjects met our study criteria including; 14 HIV, 20 HTLV-I and 6 HTLV-I/HIV co-infected subjects. For each subject, clinical staging was assigned based on the revised criteria of WHO staging system (30) by an infectious disease specialist.

The study was approved by the Research Ethics Committee of Mashhad University of Medical Sciences (No: B8797). Participants had full authority to participate in study. An informed consent was taken from participants. All information were recorded and tagged with proper identification codes to identify participants for confidentiality.

Specialized physicians examined the patients and recorded the results that were including complications related to immune system (infections, malignancies, lymphadenopathy, ext.) and general complications. All participants were completed a standard questionnaire including demographic information and the history of any current illness.

Sample collection and serological assay

Blood sample of 10 ml was collected from each participant. Serum samples were tested for the presence of anti-HTLV-I (Diapro, Italy) and anti-HIV (Diapro, Italy) by enzyme-linked immunosorbent assay (ELISA) according to manufacturer instructions in Center of Infectious Diseases (Mashhad, Iran). Positive specimens were confirmed by a conventional polymerase chain reaction (PCR). To confirm HTLV-I infection a conventional PCR was carried out for Tax and LTR region on PBMCs extracted DNA. Genomic DNA was extracted from peripheral blood mononuclear cells (PBMCs) using an available commercial kit (Blood mini kit, Qiagen, Germany) and PCR amplification was performed using specific primers for tax (5-AGGGTTTGGACAAGTCTT-3 and 5-AAGGACCTTGAGGTCTTATA-3) and LTR regions (5-ATAAGCTCAGACCTCGGG-3 and 5-GGATGGCCGCTCAGTGG-3).

HTLV-I proviral load

To assess the HTLV-I proviral load, PBMCs were isolated from EDTA-treated blood samples by Ficoll density gradient (Sigma, Germany). Genomic DNA was extracted from PBMCs using an enzymatic method (QiAamp® DNA Mini Kit) according to the manufacturer instructions. A real time PCR (Taqman probe) using an absolute quantification kit was carried out to measure the HTLV-I proviral load in PBMCs using specific primers and a fluorogenic probe which have been tested on Rotorgen Q 6000 machine (Qiagen, Germany) The HTLV-I copy number was reported as an actual amount of cellular DNA by means of the quantification of the albumin gene as the reference gene. HTLV-I and albumin DNA concentrations were calculated from two 5-point standard curves. The normalized value of the HTLV-I proviral load was calculated as the ratio of (HTLV-I DNA copies number/albumin DNA copies number/2) ×10^4 and expressed as the number of HTLV-I provirus per 10^4 PBMCs (31).
HIV viral load

To examine the HIV viral load, RNA was extracted from plasma using Viral RNA extraction Mini Kit (Qiagen, Germany). A Real Time PCR (Taqman probe) using a commercial absolute quantification kit (FTD Kit, Luxembourg) was carried out to measure HIV viral load by a Rotorgen Q machine (Qiagen, Germany).

Evaluation of CD4 and CD8 counts

CD4, CD8 and CD3 cells were stained by conjugated antibodies FITC, PE and PreCP, respectively (IQ products, the Netherlands). Cells were analyzed using a FACS Calibur (BD Bioscience, USA) flow cytometer.

Statistical analysis

Data were analyzed by Mann-Whitney and Independent Sample T Tests using SPSS/ver.16 software. Descriptive statistics were summarized as mean with standard deviation (SD) and standard error of mean (SEM). P. values of < 0.05 were considered statistically significant.

Results

Thirty seven subjects with mean age of 35.88 ± 1.89 years (ranging 22-50 years) were studied. The mean age of HIV, HTLV-I and HTLV-I/HIV co-infected subjects were 36.43 ± 2.66, 35.71 ± 3.87 and 33.67 ± 2.33 years, respectively.

The mean HTLV-I proviral load in HTLV-I infected individuals was 373.6 ± 143.3 and in HTLV-I/HIV co-infected group was 222.333 ± 82.56, the difference was statistically significant (p < 0.05). The mean HIV viral load in HIV group was 134626.07 ± 60031.07 and in HTLV-I/HIV co-infected group was 158947 ± 78203.59. There was no significant difference between two groups.

Table 1 shows the mean HTLV-I proviral load, mean HIV viral load, and mean age of patients in HTLV-I- infected group, HIV infected subjects and HTLV-I/HIV co-infected groups.

Discussion

HIV and HTLV-I are two human retroviruses that mainly contaminate CD4+ helper lymphocytes. HTLV-I/HIV co-infection has been reported in different parts of the world. Since there is a direct relationship between HIV- RNA plasma level and the clinical progression of AIDS. High HTLV-I proviral has been detected in HTLV-I related diseases which are implicated in clinical progression and severity of these diseases (8, 22, 32-35).

The results of this study show that HIV viral load in HTLV-I/HIV co-infected patients (158947 ± 78203.59) was higher than in HIV infected patients (134626.07 ± 60031.07). Furthermore, HTLV-I proviral load in HTLV-I/HIV co-infected patients (222.333 ± 82.56) is lower than in HTLV-I infected patients (373.6 ± 143.3) (p < 0.05).

The mean white blood cell count was higher in co-infected group (5666.67±1146.492 cells/μL) than both groups (P = 0.1). However, the differences between these subjects did not reach a statistical significance within 95% confidence interval (p = 0.1) level.

The CD4+ cells count in HTLV-I infected (659.9 ± 110.7) and co-infected patients (431.43 ± 120) was higher than HIV infected group (414 ± 97.5), however, the differences were not statistically significant.

Table 1: Mean HTLV-I proviral load, mean HIV viral load and mean age in HTLV-I infected patients, HIV infected and HTLV-I/HIV co-infected groups

| Variables                          | Total (n=24) | Female (n=7) | Male (n=17) |
|------------------------------------|-------------|--------------|-------------|
| HIV infected group                 | 5214.29±495.680 | 3950±288.86  | 5720±63.30  |
| HTLV-I infected group              | 5657.14±374.711 | 5933.33±709.10 | 5450±384.05 |
| HIV/HTLV-I co-infected group       | 5666.67±1146.49 | 5666.67±1146.49 |           |
| HTLV-I proviral load (mean ± SE)   | 373.6 ±143.3 | 485±300.88   | 289.75±75.06 |
| Copy number/10⁴PBMC                | 823±82.56    | 22.33±82.56  |             |
| HIV/HTLV-I co-infected group       | 38591.25±48007.03 | 155040±82572.33 |           |
| HIV viral load (mean ± SE) copies/mL plasma |            |              |             |
| HIV infected group                 | 134626.07±60031.07 | 83591.25±48007.03 | 155040±82572.33 |
| HIV/HTLV-I co-infected group       | 158947±78203.59 | 158947±78203.59 |           |
| Age (mean years)                   |            |              |             |
| HIV infected group                 | 36.43±2.66 | 30.75±5.61   | 38.70±5.25  |
| HTLV-I infected group              | 35.71±3.87 | 30±2.88      | 40±5.83     |
| HIV/HTLV-I co-infected group       | 33.67±2.33 | 33.67±2.33   | 33.67±2.33  |

WBC count: white blood cell count, SEM: standard error of mean, PBMCs: peripheral blood mononuclear cells.
group as compared to HIV group and it was positively associated with an enhancement of T-cell activation markers in both co-infected and HIV groups (37). These findings have also been confirmed by previous studies (21, 39-40). However, Harrison et al reported HTLV-I has no effect on HIV viral load. In this study, HIV viral load was higher in HIV infected group than HTLV-I/HIV co-infected group. This inconsistency might be due to the incidence of different HIV-I phenotypes in clinical disease (38, 41). Since soluble factors secreted by HTLV-I infected cells determine progression or prevention of HIV-1 infection, the real impact of HTLV-I/HIV co-infection on HIV pathogenesis is still controversial (8, 38).

In the present study, HTLV-I proviral load in HTLV-I infected patients was higher than co-infected patients (Table 1), which was statistically meaningful. Similar results were obtained by Cesaire (42). It has been demonstrated that HIV may activate HTLV-I viral expression by interaction with host cellular genes in co-infected patients and as a result could accelerate HAM/TSP development in infected individuals (18, 43-44), however, the results of our study did not show such effects.

Helper T lymphocytes (CD4+) are the main targets for HTLV-I and HIV and in case of HTLV-I and HIV; it leads to T cell proliferation (7, 8) and depletion, respectively (1). Therefore, it was assumed that the CD4 T cell count would be higher in HTLV-I infected groups. In our study, CD4+ T cells count in HTLV-I infected and co-infected groups was higher than HIV group and this difference was not statistically meaningful, although previous studies have reported that CD4+ T cell count in HTLV-I/HIV co-infected patients is higher than HIV infected individuals (19, 26, 29, 45).

In a recent study, evaluation of absolute lymphocyte count among HTLV-I/HIV co-infected and HIV infected groups showed that, lymphocyte reduction in co-infected patients occurs more slowly than in HIV infected group. This could explain the higher HTLV-I proviral load in co-infected patients due to increasing number of host cells for HIV virus. In contrast, progressive depletion of CD4+ T cells (target cells for HTLV-I virus infection) might explain the reduction of HTLV-I provirus load in the co-infected patients (37).

Furthermore, in the present study like some previous results, HTLV-I proviral load in women was higher than men and in contrast, HIV viral load in men was higher than women (Table 1) which may be due to the effects of male hormones on immune system, particularly lymphocyte count (31, 46-50).

Since, in the present study, there have been some confounding factors such as nutrition, genetic variations and economic situation, the authors tried to minimize these factors by choosing suitable control groups, HIV positive subjects in stage one, newly diagnosed cases of HIV or HTLV-I. Further studies with larger sample size might help to clarify the role of viral and host factors in HIV/HTLV-I co-infections.

Conclusion
HTLV-I/HIV co-infection could possibly increase the HIV viral load and reduce the HTLV-I proviral load. Since HTLV-I/HIV co-infection is increasing in different parts of the world, larger studies should be conducted to discover the interactions between HIV and HTLV-I and host to have a better understanding of clinical co-infection outcome, transmission and monitoring HTLV-I/HIV co-infection subjects.

Acknowledgment
The results described in this paper were part of student thesis. The authors do appreciate Dr Hassan poor, the Center of Infectious Diseases, Health center of Khorasan, Mashhad University of Medical Sciences, Mashhad, Iran for great helps. This study was financially supported by the Vice Chancellor of Research, Mashhad university of Medical Sciences, Mashhad, Iran. We do appreciate Mr Mohammadreza Ebrahimipour for proof reading the article.

References
1. Fevrier M, Dorgham K, Rebollo A. CD4+ T cell depletion in human immunodeficiency virus (HIV) infection: role of apoptosis. Viruses 2011; 3:586-612.
2. Friedrich BM, Dziuba N, Li G, Endsley MA, Murray JL, Ferguson MR. Host factors mediating HIV-1 replication. Virus Res 2011; 161:101-114.
3. Younas MZ, Zia S, Babar ME, Asif H. The epidemic of HIV/AIDS in developing countries; the current scenario in Pakistan. Virol J 2011; 8:401.
4. AIDS Progress Report-Iran,March 2012. 2012. Available at:http://www.unaid.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/IIRiran%20AIDS%20Progress%20Report%202012%20Englis h%20final1_1.pdf.
5. Johanson J, Abravaya K, Caminiti W, Erickson D, Flanders R, Leckie G, et al. A new ultrasensitive assay for quantitation of HIV-1 RNA in plasma. J Virol Methods 2001; 95:81-92.
6. Mackay IM, Arden KE, Nitsche A. Real-time PCR in virology. Nucl Acids Res 2002; 30:1292-1305.
7. Cabral F, Arruda LB, de Araujo ML, Montanheiro P, Smid J, de Oliveira AC, et al. Detection of human T-cell lymphotropic virus type 1 in plasma samples. Virus Res 2012; 163:87-90.
8. Bittes C, Sampalo J, Oliveira A. HIV/human T-cell lymphotropic virus coinfection revisited: impact on AIDS progression. AIDS Rev 2009; 11:8-16.
9. Yamashiro T, Kamiya H, Miyara T, Gigo S, Ogawa K, Akamine T, et al. CT scans of the chest in carriers of human T-cell lymphotropic virus type 1: presence of interstitial pneumonia. Acad Radiol 2012; 19:952-957.
10. Naderi M, Paryan M, Azadmanesh K, Rafatpanah H, Rezvan H, Mirab Samisee S. Design and development of a quantitative real time PCR assay for monitoring of
HTLV-1 provirus in whole blood. J Clin Virol 2012; 53:302-307.

11. Kalavi K, Moradi A, Tabarraei A. Population-based Seroprevalence of HTLV-1 Infection in Golestan Province, South East of Caspian Sea, Iran. Iran J Basic Med Sci 2013; 16.

12. Boostani R, Ardakani AM, Ashrafi H. Khorasan Disease: Prevalence of HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in West Azerbaijan from 2004 to 2007. Iran Red Crescent Med J 2011; 13:428.

13. Azarpazhooh MR, Hasnapour K, Ghanbari M, Rezaee SR, Mashkani B, Hedayat-Moghadam MR, et al. Human T-lymphotropic virus type 1 prevalence in Northeastern Iran, Sabzevar: an epidemiologic-based study and phylogenetic analysis. AIDS Res Hum Retroviruses 2012; 28:1095-101.

14. Sadeghian MH, Keramati MR, Ayatollahi H, Feizabadi AS, Tehranaian F, Shakibye B. Is there any relationship between expressions of minor blood group antigens with HTLV-1 infection? Transfus Apher Sci 2012; 47:151-154.

15. Vakili R, Sabet F, Ghezeldasht SA, Boostani R, Rafatpanah H, Shamsian A, et al. Human T-lymphotropic virus type I (HTLV-1) proviral load and clinical features in Iranian HAM/TSP patients. Iran J Basic Med Sci 2013; 16.

16. Rafatpanah H, Hosseini RF, Pourseyed SH. The Impact of immune response on HTLV-I in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Iran J Basic Med Sci 2013; 16.

17. Belike MA, Traina-Dorge VL, Sirois M, Bhuiany A, Murphy EL, Walls JM, et al. Relationship between human T lymphotropic virus (HTLV) type 1/2 viral burden and clinical and treatment parameters among patients with HIV type 1 and HTLV-1/2 coinfection. Clin Infect Dis 2007; 44:1229-1234.

18. Casseb J, de Oliveira AC, Vergara MP, Montanheiro P, Bonasser F, Meilman Ferreira C, et al. Presence of tropical spastic paraparesis/human T-cell lymphotropic virus type 1-associated myelopathy (TSP/HAM)-like among HIV-infected patients. J Med Virol 2008; 80:392-398.

19. Silva MT, Neves ES, Grinsztejn B, de Melo Espindola S, Schor D, Araujo A. Neurological manifestations of coinfection with HIV and human T-lymphotropic virus type 1. AIDS (London, England) 2012; 26:521-523.

20. Bassani S, Lopez M, Toro C, Jimenez V, Sempere JM, Soriano V, et al. Influence of human T cell lymphotropic virus type 2 coinfection on virological and immunological parameters in HIV type 1-infected patients. Clin Infect Dis 2007; 44:105-110.

21. Belike MA, Thell KJ, O'Brien M, Clayton JL, Benjamin SM, Winsor EL, et al. Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2. Clin Infect Dis 2004; 39:256-263.

22. Regis C, Oliveira A, Brites C. Onset of opportunistic infections in patients co-infected by HTLV-1 and HIV-1, with high CD4+ cells count. Braz J Infect Dis 2009; 13:311-313.

23. Taltynov O, Desimmie BA, Demeulemeester J, Christ F, Debyser Z. Cellular cofactors of lentiviral integrase: from target validation to drug discovery. Mol Biol Int 2012; 2012:863405.

24. O'Connor GM, Seich Al Basatena NK, Olavarria V, MacNamara A, Vine A, Ying Q, et al. In contrast to HIV, KIR3DS1 does not influence outcome in HTLV-1 retroviral infection. Hum Immunol 2012; 73:783-787.

25. Quaranta MG, Mattioli B, Vella S. Glances in Immunology of HIV and HCV Infection. Adv Virol 2012; 2012:434036.

26. Norrgren H, Bamba S, Da Silva ZJ, Koivula T, Andersson S. Higher mortality in HIV-2/HTLV-1 co-infected patients with pulmonary tuberculosis in Guinea-Bissau, West Africa, compared to HIV-2-positive HTLV-1-negative patients. Int J Infect Dis 2010; 3:e142-147.

27. Bahia F, Novaí V, Evans J, Le Marchand C, Netto E, Page K, et al. The impact of human T-cell lymphotropic virus I infection on clinical and immunologic outcomes in patients coinfected with HIV and hepatitis C virus. J Acquir Immune Defic Syndr 2011; 57:S202-207.

28. Belike MA, Japa S, Moeller-Hadi C, Martin-Schild S. Tropical spastic paraparesis/human T leukemia virus type 1-associated myelopathy in HIV type 1-coinfected patients. Clin Infect Dis 2005; 41:e57-63.

29. Casseb J, Posada-Vergara MP, Montanheiro P, Fukumori LM, Olah I, Smid J, et al. T CD4+ cells count among patients co-infected with human immunodeficiency virus type 1 (HIV-1) and human T-cell leukemia virus type 1 (HTLV-1): high prevalence of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). Rev Inst Med Trop de Sao Paulo 2007; 49:231-233.

30. WHO. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2006. Available from: http://www.who.int/hiv/pub/vct/hivstaging/en/index.html.

31. Rafatpanah H, Rezaee A, Ettemadi MM, Hosseini RF, Khorram B, Afsahr L, et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran. J Neuroimmunol 2012; 250:87-93.

32. Swanson P, Harris BJ, Holzmayer V, Devare SG, Schochetman G, Hackett J Jr. Quantification of HIV-1 group M (subtypes A-G) and group O by the LCx HIV RNA quantitative assay. J Virol Methods 2000; 89:97-108.

33. Altamirano NA, Rocco C, Aulicino P, Sen L, Mangano A. Quantitation of HTLV-I proviral load by a real-time PCR assay using SYBR Green: comparison of two methods for DNA isolation. J Virol Methods 2010; 170:160-164.

34. Machuca A, Rodes B, Soriano V. The effect of antiretroviral therapy on HTLV infection. Virus Res 2001 30; 78:93-100.

35. Alimonti JB, Ball TB, Fowke KR. Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gene Virol 2003; 84:1649-1661.

36. Chan JK, Greene WC. Dynamic roles for NF-kappaB in HTLV-I and HIV-1 retroviral pathogenesis. Immunol Rev 2012; 246:286-310.

37. Pedroso C, Netto EM, Weyl N, Brites C. Coinfection by HIV-1 and human lymphotropic virus type 1 in Brazilian children is strongly associated with a shorter survival time. J Acquir Immune Defic Syndr 2011; 57:S208-211.
38. Casoli C, Pilotti E, Bertazzoni U. Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression. AIDS Rev 2007; 9:140-149.
39. Schechter M, Harrison LH, Halsey NA, Trade G, Santino M, Moulton LH, et al. Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil: Impact on markers of HIV disease progression. JAMA 1994; 271:353-357.
40. Fantry L, De Jonge E, Auwaerter PG, Lederman HM. Immunodeficiency and elevated CD4 T lymphocyte counts in two patients coinfected with human immunodeficiency virus and human lymphotropic virus type I. Clin Infect Dis 1995; 21:1466-1468.
41. Harrison LH, Quinn TC, Schechter M. Human T cell lymphotropic virus type I does not increase human immunodeficiency virus viral load in vivo. J Infect Dis 1997; 175:438-440.
42. Casrade R, Dehee A, Lezin A, Desire N, Bourdonne e O, Dantin F, et al. Quantification of HTLV type I and HIV type I DNA load in coinfected patients: HIV type I infection does not alter HTLV type I proviral amount in the peripheral blood compartment. AIDS Res Hum Retroviruses 2001; 17:799-805.
43. Harrison LH, Schechter M. Coinfection with HTLV-I and HIV: increase in HTLV-I-related outcomes but not accelerated HIV disease progression? AIDS patient care and STDs 1998; 12:619-623.
44. Roy U, Simpson SA, Mondal D, Eloby-Childress S, Winsor EL, Beilke MA. Upregulation of HTLV-1 and HTLV-2 expression by HIV-1 in vitro. J Med Virol 2008; 80:494-500.
45. Brites C, Oliveira AS, Netto EM. Coinfection with HIV and human T lymphotropic virus type I: what is the real impact on HIV disease? Clin Infect Dis 2005; 40:329-330.
46. Matsuzaki T, Nakagawa M, Nagai M, Usuku K, Higuchi I, Arimura K, et al. HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J Neurovirol 2001; 7:228-234.
47. Adau V, Verdonck K, Best I, Gonzalez E, Tipismana M, Arevalo J, et al. SYBR Green-based quantitation of human T-lymphotropic virus type I proviral load in Peruvian patients with neurological disease and asymptomatic carriers: influence of clinical status, sex, and familial relatedness. J Neurovirol 2006; 12:456-465.
48. Donnelly CA, Bartley LM, Ghani AC, Le Fevre AM, Kwong GP, Cowling BJ, et al. Gender difference in HIV-1 RNA viral loads. HIV Med 2005; 6:170-178.
49. Napravnik S, Poole C, Thomas JC, Eron JJ Jr. Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr 2002; 31:11-19.
50. Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, Greenblatt RM. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis 2002; 35:313-322.